Science1 publisher2 min readPublished
CIC biomaGUNE reports MRI contrast from 5 nm manganese-doped carbon nanodots on par with commercial agents
CIC biomaGUNE researchers say 5 nm carbon nanodots with a little manganese matched, and in some cases beat, current MRI contrast agents. That adds to the case for manganese in place of gadolinium, though every safety result so far comes from cells and animals.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Lucia Cardo and Maurizio Prato of CIC biomaGUNE led the study, which appears in the journal ACS Nano.
- Gadolinium compounds, the usual MRI contrast agents for almost four decades, may pose a health risk for patients with kidney failure.
- Manganese is being studied as a replacement because it is considered safer and more abundant, and it costs less than other heavy metals.
- The nanodots are also fluorescent, so a single particle could in principle be read by MRI and by other detection methods.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- capability Because the bare dot already shows up on MRI, targeting groups or drugs could be added later to a base whose imaging signal does not depend on them.
- precedent If other labs adopt the group's validation checks, they would address the batch-to-batch problem Cardo describes for carbon nanodots in general, beyond this one MRI use.
- constraint Patients with kidney failure are the group a gadolinium substitute would serve first, so how the dots clear when kidneys work poorly is the next safety question to answer.
"Despite being present only in small amounts, the manganese is firmly integrated into the structure of the nanoparticle, so its properties can be exploited to provide exceptional contrast in MRI. In fact, its performance is comparable to current contrast agents, or even superior in some cases," Cardo said [5].
That comparison comes from the team. The phys.org account of the ACS Nano paper does not say which commercial agents were the benchmark, what quantity was measured, at what dose, or by how much the dots came out ahead in the cases where they did [3]. I would want those figures before leaning on the word "comparable".
In my view the reproducibility work is the stronger result. The stated aim was a first platform that is stable, reproducible, well tolerated and detectable by MRI [8]. Cardo said that "achieving adequate stability and reproducibility remains one of the main challenges in translating them from research to real-world biomedical applications" [9]. Alongside optimising the synthesis, she said, the group "established validation strategies that allow us to obtain a truly reliable and reproducible material" [10].
Michele Cesco, the paper's lead author [11], pointed to a design choice that makes the imaging result easier to interpret. "An important contribution of this work was that the nanodots could be detected in their natural form using MRI," he said, "without having to first add a molecule that targets them toward a specific organ or tissue, something that usually contributes to their accumulation and, hence, their detection." [12] With no targeting molecule pulling the particles into one tissue, what appears on the scan reflects the dot's own contrast and its ordinary spread through the body [12].
The safety evidence covers cells and animals, including long-term studies, in which the particles were efficiently eliminated and highly biocompatible [1]. Cardo said the team "observed adequate biodistribution and rapid elimination from the body, without detecting any significant toxic effects on the main organs analyzed" [2].
The group's next step is theranostics, putting detection and treatment on the same particle [14].
What to watch
- The ACS Nano paper's own comparison data: which commercial agents were the benchmark, what was measured, and by what margin the dots came out ahead.
- Whether the theranostic versions the group is now pursuing keep the MRI contrast of the bare, untargeted dots.